The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > REGULATORY
REGULATORY
- Preparations Underway for MHLW to Set Up Private Third-Party Committee
September 16, 2011
- Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain
September 16, 2011
- US FDA Issues Warning Letter Over GMP Violations by Daiichi Sankyo Subsidiary
September 15, 2011
- MHLW to Survey “Family Pharmacy” Function Toward Next Revision of Dispensing Fees
September 15, 2011
- US Proposes Elimination of Tariff on Drugs: TPP Talks
September 14, 2011
- MHLW to Continue to Promote Non-proprietary Name-based Brand Names for GE Drugs
September 14, 2011
- ”GMP Team” to Begin Mock GMP Inspections in Kinki Region from Next February
September 14, 2011
- MHLW Permits Ongoing Internet Sales of Reclassified Class 2 Drugs as Provisional Measure
September 13, 2011
- MHLW Minister Komiyama to Push Drug Industry Development Through Government-Private Sector Cooperation
September 13, 2011
- PAFSC: “No Direct Correlation” Between HPV Vaccine and Reported Death
September 13, 2011
- MHLW Director-General Kikura Indicates “Firm Resolve” for Structural Improvement to Eliminate Drug Disasters
September 12, 2011
- Regulatory Strategy Consultation Service “Not Off to a Good Start”: Mr Masuyama of PMDA
September 12, 2011
- Dispensing Fees per Prescription Down in FY2010 for 1st Time in 4 Years: Korosho
September 12, 2011
- Japan-China Pharma Regulators to Start 4 Projects to Boost Cooperation
September 12, 2011
- MHLW Designates 6 Products Including ruxolitinib as Orphan Drugs
September 9, 2011
- Medical Costs Reduced ¥7 Bil. by Promoting Use of GEs: JHIA
September 9, 2011
- MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
- Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 8, 2011
- Generic Dispensing Not Promoted in Pharmacies: CSIMC’s Subcommittee
September 8, 2011
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…